Collects samples and health information from people with cancer for research
Collects tissue samples, scans and questionnaires from people with cancer for research.
Plain-language title generated from the registry record
Registry title: SPECTA: Screening Cancer Patients for Efficient Clinical Trial Access
Key facts
- Where
- Vienna, AustriaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people aged 12 or older with a confirmed type of cancer. It collects tumor samples, images and questionnaires to support cancer research.
- Age
- 12 years or older
- Sex
- All sexes can join.
- Disease stage
- Cancer that has been confirmed under the microscope for selected tumor types.
Main reasons for not taking part
- Not enough good-quality tumor or other biological material
- Any psychological, family, social or geographical situation that could get in the way of following the study plan and follow-up visits
- No written informed consent
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- How old is the patient who may join a trial?
Source: NCT02834884, who can take part
Where in Austria
- Medical University Vienna - General Hospital AKHVienna, AustriaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- European Organisation for Research and Treatment of Cancer - EORTC
- Trial code
- NCT02834884
- Record updated
- 24 June 2026
- Original description
SPECTA is a quality assured platform for collecting clinicopathologically annotated biological material, imaging data, operative images, environmental assessment, questionnaires as well as patient-reported outcomes from cancer patients to support biospecimen-based translational research and clinical cancer research, including biomarker discovery to improve the understanding of tumor biology and cancer patients care.Read full original descriptionShow less
SPECTA: Screening Cancer Patients for Efficient Clinical Trial Access
SPECTA is a quality assured platform for collecting clinicopathologically annotated biological material, imaging data, operative images, environmental assessment, questionnaires as well as patient-reported outcomes from cancer patients to support biospecimen-based translational research and clinical cancer research, including biomarker discovery to improve the understanding of tumor biology and cancer patients care.
Patients with pathologically confirmed selected tumor types (at site or centrally); Mandatory availability of adequate human biological material (HBM); Centrally performed confirmation of HBM adequacy in terms of quality and quantity for SPECTA downstream project requirements; Age ≥ 12 years; Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; Written informed consent according to applicable legal and ethical requirements.